Compare KVUE & AFRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVUE | AFRM |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Business Services |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9B | 28.3B |
| IPO Year | 2023 | 2020 |
| Metric | KVUE | AFRM |
|---|---|---|
| Price | $19.07 | $76.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 25 |
| Target Price | $19.45 | ★ $84.52 |
| AVG Volume (30 Days) | ★ 18.6M | 3.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.82% | N/A |
| EPS Growth | 40.74 | ★ 108.98 |
| EPS | 0.48 | ★ 0.90 |
| Revenue | ★ $15,124,000,000.00 | $3,224,412,000.00 |
| Revenue This Year | $4.85 | $30.78 |
| Revenue Next Year | $2.63 | $23.95 |
| P/E Ratio | ★ $78.64 | $87.19 |
| Revenue Growth | N/A | ★ 38.80 |
| 52 Week Low | $14.02 | $42.10 |
| 52 Week High | $21.96 | $100.00 |
| Indicator | KVUE | AFRM |
|---|---|---|
| Relative Strength Index (RSI) | 56.88 | 54.70 |
| Support Level | $16.83 | $60.58 |
| Resistance Level | $20.09 | $79.18 |
| Average True Range (ATR) | 0.44 | 2.84 |
| MACD | -0.01 | 0.28 |
| Stochastic Oscillator | 64.26 | 73.05 |
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
Founded in 2012, Affirm is a market leader in the buy now, pay later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also constitute the majority of its revenue. Affirm primarily operates in the United States, which accounted for more than 95% of its revenue in 2025, but it has also expanded to Canada and the United Kingdom.